Bangbang Robotics Secures Nearly RMB 100 Million in Series B Funding to Accelerate Global Expansion and Next-Gen Smart Mobility Solutions

VCBeat has learned that Shanghai Bangbang Robot Co., Ltd. (hereinafter referred to as “Robooter”), an emerging force in assistive mobility technology, recently announced the completion of its Series B financing round, raising nearly RMB 100 million. The round was co-led by top-tier healthcare investment firms Qichi Capital and Boyuan Capital, with participation from Zero One Ventures and continued support from existing shareholder Changling Capital. Joyful Capital served as the exclusive financial advisor for this financing round.

Robooter Product Video

The proceeds from this financing round will primarily be used to accelerate the production and commercialization of multiple new products currently under development at Robooter, while also actively advancing its overseas market expansion to help the company rapidly secure a leading position in the global assisted mobility sector.

Improving mobility for individuals with disabilities represents a vast market, with the accelerating aging population further driving an explosive surge in demand for mobility assistance. In 2020 alone, the market size of rehabilitation mobility aids in China reached RMB 25 billion, while the global market exceeded RMB 100 billion, maintaining a steady annual growth rate of 5%–10%.

The emergence of Generation 1.0 assistive mobility products, such as canes and manual wheelchairs, transformed the helpless situation humans faced in dealing with mobility impairments. With rapid technological advancements and improved living standards, users’ demand for “more efficient” products has intensified, giving rise to Generation 2.0 of assistive mobility, represented by electric wheelchairs, electric scooters, and power-assist devices. Today, with the rapid development of chip technology, new materials, high-performance motors, and the Internet of Things (IoT), user needs for assistive mobility have further evolved toward greater safety, intelligence, enhanced service experience, and stronger environmental adaptability, ushering in the gradual arrival of Generation 3.0 of assistive mobility.

Robooter, leveraging its robust R&D capabilities, has successively launched two representative smart products of the 3.0 era, epoch-makingly meeting the needs of individuals with mobility challenges for"Intelligent Services + Proactive Safety Protection + Multi-Environment Adaptability"...of anticipation for cutting-edge technology. Among these innovations, intelligent assistive mobile robots can help individuals with mobility impairments truly achieve independence and ease within their homes, while consumer-grade mobility robots enable users with limited mobility to travel safely and steadily. Grounded in in-depth user research and driven by the aspiration for every user to return to daily life with greater confidence, the company’s core products have won top awards at international industrial design competitions, setting new benchmarks for aesthetic excellence in the industry.

At the service level, Robooter’s intelligent products integrate IoT and AI technologies, delivering users with unexpectedly superior services across a wider range of scenarios, including positioning services, emergency alerts, remote after-sales support, and beginner mode. In terms of professional rehabilitation guidance, the company’s remote rehabilitation training system breaks down spatial and temporal barriers among users, family members, and healthcare professionals, enabling users to access real-time, professional, interactive rehabilitation services at any time.

Technological innovation is the golden key for Robooter to revolutionize the traditional market of rehabilitation and mobility assistive devices. The company’s core R&D team primarily consists of alumni from Harbin Institute of Technology, known as “the cradle of robotics in China.” With over a decade of accumulated R&D experience, the company has not only established“Robotics Intelligent Connected System Platform + Remote Rehabilitation Service Platform”The company has two core platforms and a series of products with preliminary AIoT capabilities. In the field of core product components, it has achieved full in-house control of key technologies—from motors and control systems to omnidirectional wheels—and maintains an industry-leading position. To date, the company holds more than 110 patents, including three international invention patents.

In terms of multi-scenario intelligent applications for low-speed mobility products, Robooter has achieved leading R&D results in active environmental monitoring, assisted safe driving, and autonomous driving solutions for closed campuses. Furthermore, the company has made significant progress in cost-effectively transforming these technologies into modular products. In the future, as various scenario-based applications mature, the smart mobility industry is bound to usher in a new era.

To date, disabled persons’ federations and work-related injury equipment provision departments across many regions in China have included selected Robooter products in their recommended catalogs, and multiple cities have incorporated several Robooter products into the rental catalogs covered by long-term care insurance. The company’s technical team also served as a primary drafter for the standard T/CAAP “Intelligent Electric Transfer Vehicle.” Multiple company products have received awards for the transformation of high-tech achievements. Both the Robooter Intelligent Assistive Mobility Robot and the Robooter Mobility Scooter have been included in the Ministry of Industry and Information Technology’s recommended catalog for home service robots. The company has also been honored with titles such as “Specialized, Refined, Differential, and Innovative” enterprise.

Leading R&D capabilities and keen market insights have driven strong demand for Robooter in the end-user market. Since its launch, the product has entered nearly 20 countries across five continents, with cumulative sales rapidly surpassing 10,000 units. Compared with overseas brands, Robooter’s products, thanks to their robust quality and significant price advantage, are often highly sought after even during trial sales phases.

Since its inception, Robooter has been committed to leveraging technology to enhance the quality of life for individuals with disabilities. In addition to manufacturing high-quality assistive devices, the company is actively building a rehabilitation service system tailored to the needs of this population. Looking ahead, Robooter plans to expand into B2B scenarios such as airports and industrial parks, utilizing intelligent solutions to meet a broader range of mobility needs.

Mr. Li Jianguo, Founder of Bangbang Robotstated that the assisted mobility industry is a sector of profound social significance that embodies the principle of “tech for good.” Robooter is committed to bringing Chinese intelligent manufacturing to markets worldwide, serving a broader population in need. We look forward to delivering more exciting innovations in this industry!

Ms. Qian Ranting, PE Partner at Qingchi CapitalIt stated that intelligent mobility assistance devices are essential necessities for major countries worldwide as they enter an aging society, and are also indispensable for demonstrating care for individuals with mobility impairments and promoting social equity and well-being. The Robooter team has accumulated substantial technical expertise over many years in the field of intelligent rehabilitation and mobility assistance devices, demonstrating originality and forward-thinking in the independent research and development of core components and product portfolio planning. Leveraging its intelligent robotics technology platform, the company pursues parallel development to drive the iteration of both medical-grade and consumer-oriented product lines, aiming to serve a broader domestic and international customer base and meet more diverse user needs. We recognize the Robooter team’s spirit of exploration and execution capabilities; given time, Robooter has the potential to become an industry-leading expert in intelligent rehabilitation and mobility solutions.

Mr. Liu Kai, Managing Director at Boyuan CapitalIt is stated that the aging trend in China and across the globe is stimulating the vigorous development of the silver economy. As essential products addressing the basic living needs of the elderly, assisted mobility devices are poised to spearhead the formation of a robust new consumer market within the silver economy, characterized by strong and sustained demand. Robooter products have always centered on users’ actual needs, undergoing rigorous refinement in structural design, mechatronic integration, and manufacturing processes. Leveraging strong technical capabilities, the company has independently developed smart mobility solutions that integrate performance, aesthetics, and lightweight design, rapidly establishing itself as a competitive brand in the global assisted mobility market. We are optimistic that the Robooter team, upheld by its valuable spirit of innovation and steadfast commitment to deep industry engagement, will become the preferred lifestyle partner for more customers both domestically and internationally in the future.

Mr. Tao Yangfeng, Vice President of Zero One VenturesHe stated that the Robooter team has been deeply engaged in the field of rehabilitation and nursing robots for many years, adhering to independent research and development, and has achieved remarkable results in both intelligent rehabilitation and mobility assistance. With the intensifying aging population, this market holds enormous potential. Zero One Ventures has always focused on investment opportunities in technology-driven supply chain upgrades and has made in-depth investments in technology applications within supply chain scenarios. Meanwhile, we are optimistic about the structural opportunities arising from supply chain spillovers and are actively positioning ourselves in the cross-border expansion sector. Therefore, we have been closely monitoring the opportunities for the globalization of China’s technology supply chain. Robooter’s products have already entered international markets, and we believe that Robooter will leverage the advantages of China’s technology supply chain to achieve even greater success in global expansion in the future.

Mr. Jiang Xiaodong, Managing Partner at Changling CapitalIt was stated that as China’s population ages rapidly, the digital divide between the elderly and technological products has become increasingly prominent. The Robooter team has seized upon this critical issue, leveraging its robust technical expertise to innovatively apply advanced technologies—such as chips, new materials, electric motors, and the Internet of Things (IoT)—to the fields of smart mobility and rehabilitation for elderly users. By enabling vulnerable social groups to share in the benefits of the latest technological advancements through commercial products, this approach not only holds significant commercial value but also carries profound social significance in China’s new era of pursuing common prosperity. As a long-standing shareholder, Changling Capital remains optimistic about Robooter’s future development potential and is committed to collaborating with more tech entrepreneurs to make technology-enabled elder care a gift of our times.

Mr. Guo Yixin, Managing Director at Haoyue CapitalHaoYue Capital is honored to have served as the exclusive financial advisor for Robooter’s latest round of financing, assisting the company in successfully closing the deal. The rehabilitation and elderly care industry is a key sector supported under the “14th Five-Year Plan for National Health.” As structural aging becomes increasingly pronounced across society, providing high-quality assistive devices and rehabilitation services to individuals with lower-limb mobility impairments is set to become another compelling example of “tech for social good.” As an industry leader, Robooter adheres to the R&D philosophy of “starting with users and ending with meeting their needs,” achieving remarkable speed—dubbed the “Robooter Speed”—across product development, production, and sales. Looking ahead, with further advancements in R&D capabilities, continued integration of the supply chain, and rapid expansion into overseas markets, we remain optimistic about the company’s growth prospects and look forward to Robooter’s continued success.

Headquartered in Hong Kong, China and Shanghai, Lake Bleu Capital is an investment platform focused on the healthcare sector, with assets under management totaling billions of U.S. dollars. Its secondary market USD fund is one of the largest healthcare-focused secondary market funds in Asia. Owing to its outstanding investment performance, the fund has been repeatedly recognized by authoritative institutions as the Best Secondary Market Fund in Asia, and in 2020, it received the sole award for “Best Secondary Market Fund over the Past 5 Years: Above USD 500 Million Category” from AsiaHedge. Lake Bleu Capital is also active in private equity investments within the healthcare industry across Greater China, having successfully invested in nearly 60 high-quality companies. The firm provides diversified value-added services, supporting its portfolio companies in capital operations and business collaborations.

BioTrack Capital, established in 2017, is a specialized investment firm dedicated to investing in and incubating outstanding healthcare startups in the Chinese market. Currently, BioTrack Capital manages two RMB funds and two USD funds, with total assets under management exceeding RMB 7 billion. More than just an investor, BioTrack Capital serves as a long-term partner to entrepreneurs. Since its inception, the firm has remained committed to an entrepreneur-centric approach, providing sustained support and active empowerment to exceptional founders in the healthcare sector, fostering an industry ecosystem, and cultivating the next generation of leading enterprises in China’s healthcare industry.

Zero One Ventures is an early-stage venture capital firm dedicated to “driving industrial internet and cross-border globalization through supply chain upgrades,” with a focus on investments in technology-driven supply chains and cross-border expansion. We are committed to serving as co-founders to entrepreneurs and helping the new generation of Chinese enterprises go global. Since its establishment in 2015, Zero One Ventures has been ranked among the Top 30 Early-Stage Investment Institutions by Zero2IPO for eight consecutive years. Its investment portfolio includes Lalamove, Hai Robotics, XTransfer, Xendit, E-MRO, Xiaoman Technology, Huodada, M-Zhan, Mangatoon, Hande, Hibobi, QingFlow, and Zhenwei Xiao Meiyuan.

Changling Capital, established in 2016, is a new generation of theme-driven venture capital fund. The founding partners of Changling come from NEA (New Enterprise Associates), one of the largest venture capital funds in the United States, and were responsible for NEA’s investments in China from 2005 to 2015. In the fields of healthcare and aging, Changling Capital is committed to investing in technology-driven business model innovations, making longevity a gift of life to everyone in the rapidly aging Chinese society. Changling Capital has offices in Shanghai and Beijing, currently managing a total fund size of 6 billion yuan. Its investors include endowments from globally renowned universities and hospitals, foundations, pension funds, top-tier fund-of-funds, and other first-class investment institutions. In both Shanghai and Beijing, the investment team collectively possesses over 50 years of venture capital experience, dedicated to continuously creating value for the growth and development of companies in emerging sectors.

Haoyue Capital, established in January 2014, is a leading industry-focused investment bank in China specializing in the healthcare sector. Headquartered in Shanghai, the firm maintains regional offices in Beijing and Shenzhen. Committed to leveraging capital and research-driven insights, Haoyue Capital facilitates the successful connection of outstanding Chinese healthcare enterprises with capital markets, thereby creating added value for its clients. The partnership team comprises senior investment bankers with extensive experience in China’s healthcare sector, supported by a professional team of over 70 members. Haoyue Capital closely monitors dynamics and trends in the healthcare investment market, with its research and transaction coverage spanning multiple sub-sectors, including biopharmaceuticals, innovative medical devices, IVD and life sciences, health services, and smart healthcare. In 2021, the firm completed more than 50 complex transactions involving private equity financing, mergers and acquisitions, and spin-offs of listed companies, with a total transaction value amounting to tens of billions of RMB, securing a leading position across various healthcare sub-sectors.